Product Standard

2-2-Bromoethyl-13-dioxane ,CAS number:33884-43-4,which is an intermediates of Larotrectinib,Larotrectinib (LOXO 101) is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change.Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is "tissue agnostic"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Price Advantage

With excellent R&D team and factory, product production process, we are able to offer you very competitive price.

Quality Assurance

Compliant with ISO and GMP system, strict shipping inspection procedures, COA/MSDS/ROS/MOA provided for each shipment.

Quick Response

Our pre-sales team is on call 24 hours a day to respond quickly to your needs.

http://www.tantuchemicals.com/